Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to treat polycythemia vera.

Related Posts

Partnering for success in early phase clinical development

Feb 24, 2025  0

Arvinas gets positive breast cancer data, but finds dif...

Mar 11, 2025  0

Biotech CEOs, VCs urge Cassidy, Senate to ease impact o...

Apr 10, 2025  0

Comments

Name

Email

Comment

Post Comment